VYNE

VYNE Therapeutics Inc.

VYNE Therapeutics Inc. (VYNE) has 19 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Jul 24, 2026.

  • Industry:Biotechnology
  • CEO:David T. Domzalski
  • Employees:10
  • HQ:Stewartsville, NJ, US
  • IPO:2018-01-25

No open-market insider trades for VYNE (VYNE Therapeutics Inc.) in the last 365 days.

Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.

Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.

See all Form 4 filings on SEC EDGAR ↗

Related companies

VYNE Therapeutics Inc. is in the Healthcare sector.